Duan Zhenya, Ye Yunqing, Li Zhe, Zhang Bin, Liu Qingrong, Zhao Zhenyan, Wang Weiwei, Yu Zikai, Zhang Haitong, Zhao Qinghao, Wang Bincheng, Lv Junxing, Guo Shuai, Ren Haocheng, Gao Runlin, Xu Haiyan, Wu Yongjian
Department of Cardiology, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 167 Beilishi Road, Beijing 100037, China.
Medical Research & Biometrics Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
Int J Cardiol Cardiovasc Risk Prev. 2024 Mar 13;21:200259. doi: 10.1016/j.ijcrp.2024.200259. eCollection 2024 Jun.
Rheumatic valvular disease (RVD) represents a significant health concern in developing countries, yet a scarcity of detailed data exists. This study conducts a comprehensive examination of RVD patients in China, exploring aspects of the disease's spectrum, characteristics, investigation, management, and outcomes.
The China Valvular Heart Disease (China-VHD) study, a nationwide, multicenter, prospective observational study, enrolled 13,917 adults with moderate-to-severe valvular heart disease from April to June 2018. Among these, 2402 patients with native RVD (19.7% of native VHD patients) were analyzed.
Among the RVD patients, the median age was 57 years (interquartile range 50-65), with 82.5% falling within the 40-70 age range; females were notably predominant (63.9%). Rheumatic etiology prevailed, particularly in southern regions (48.8%). Multivalvular involvement was observed in 47.4% of RVD cases, and atrial fibrillation emerged as the most common comorbidity (43.2%). Severe RVD affected 64.2% of patients. Valvular interventions were undertaken by 66.9% of RVD patients, predominantly involving surgical valve replacement (90.8%). Adverse events, encompassing all-cause mortality and heart failure hospitalization, occurred in 7.3% of patients during the 2-year follow-up. Multivariable analysis identified factors such as age, geographical region, low body mass index, renal insufficiency, left atrial diameter, and left ventricular ejection fraction <50% (all P < 0.05) associated with adverse events, with valvular intervention emerging as a protective factor (HR: 0.201; 95%CI: 0.139 to 0.291; p < 0.001).
This study delivers a comprehensive evaluation of RVD patients in China, shedding light on the spectrum, characteristics, investigation, management, and outcomes of this prevalent condition.
风湿性瓣膜病(RVD)在发展中国家是一个重大的健康问题,但详细数据匮乏。本研究对中国的RVD患者进行了全面检查,探讨了该疾病的谱系、特征、检查、管理及预后等方面。
中国瓣膜性心脏病(China-VHD)研究是一项全国性、多中心、前瞻性观察性研究,于2018年4月至6月纳入了13917例中重度瓣膜性心脏病成人患者。其中,对2402例原发性RVD患者(占原发性VHD患者的19.7%)进行了分析。
在RVD患者中,年龄中位数为57岁(四分位间距50 - 65岁),82.5%的患者年龄在40 - 70岁之间;女性明显居多(63.9%)。风湿病因占主导,尤其在南方地区(48.8%)。47.4%的RVD病例存在多瓣膜受累,房颤是最常见的合并症(43.2%)。64.2%的患者患有重度RVD。66.9%的RVD患者接受了瓣膜干预,主要是外科瓣膜置换(90.8%)。在2年随访期间,7.3%的患者发生了包括全因死亡和心力衰竭住院在内的不良事件。多变量分析确定年龄、地理区域、低体重指数、肾功能不全、左心房直径和左心室射血分数<50%等因素(均P < 0.05)与不良事件相关,瓣膜干预是一个保护因素(HR:0.201;95%CI:0.139至0.291;p < 0.001)。
本研究对中国的RVD患者进行了全面评估,揭示了这种常见疾病的谱系、特征、检查、管理及预后情况。